Dr. Randall of Tumor Sequencing Research in Sarcomas

Video

In Partnership With:

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

R. Lor Randall, MD, FACS, professor and The David Linn Endowed Chair for Orthopaedic Surgery, University of California Davis Health, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Research is looking into deep sequencing tumors to look for mutations that can be targeted with the cadre of biotargeting agents in primary bone and tissue sarcomas, explains Randall. Patients with these tumors eligible for chemotherapy will receive it in a conventional form. If they fail conventional chemotherapy, they will move on to more targeted agents, says Randall.

At the University of California Davis Health, when sarcoma is diagnosed based on biopsy, some of the original tumor is stored for precision medicine treatments, concludes Randall.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center